PREFER looks at how and when it is best to perform and include patient-preference in decision making during the drug life cycle.

They include patient stakeholders at every level of the project.

The end-result will be recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies.

Project start date – October 2016
Project end date – September 2021

Funded by IMI - innovative medicines initiative

Coordinated by

Mats G. Hansson, Professor of Biomedical Ethics and Director of the Centre for Research Ethics & Bioethics (CRB) at Uppsala University